COST-EFFECTIVENESS MODEL FOR DENOSUMAB INCORPORATING FRAX® AND ADHERENCE IN A UK SETTING

被引：0
|
作者：
Strom, O. [1 ,2 ]
Macarios, D. [3 ]
Badamgarav, E. [3 ]
Borgstrom, F. [1 ,2 ]
Jonsson, B. [1 ,4 ]
Tosteson, A. [5 ]
Kanis, J. [6 ]
机构：
[1] I3 Innovus, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Stockholm Sch Econ, S-11383 Stockholm, Sweden
[5] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[6] WHO Collaborating Ctr, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF BALLOON KYPHOPLASTY IN PATIENTS WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN A UK SETTING
    Strom, O.
    Leonard, K.
    Cooper, C.
    Marsh, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A441 - A441
  • [32] Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting
    Strom, O.
    Leonard, C.
    Marsh, D.
    Cooper, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 (09) : 1599 - 1608
  • [33] The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting
    Hakimi, Zalmai
    Wilson, Koo
    McAughey, Eoin
    Pochopien, Michal
    Wojciechowski, Piotr
    Toumi, Mondher
    Knight, Chris
    Sarda, Sujata P.
    Patel, Nikita
    Wiseman, Catherine
    de Castro, Nuno Pinto
    Nazir, Jameel
    Kelly, Richard J.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (13) : 969 - 985
  • [34] Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
    Johannesson, M
    Meltzer, D
    OConor, RM
    [J]. MEDICAL DECISION MAKING, 1997, 17 (04) : 382 - 389
  • [35] Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
    Hiligsmann, Mickael
    Reginster, Jean-Yves
    [J]. BONE, 2010, 47 (01) : 34 - 40
  • [36] A cost-effectiveness model of topiramate treatment for newly diagnosed epilepsy in the UK
    Remak, E.
    Hutton, J.
    Price, M.
    Peeters, K.
    Adriaenssen, I.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 85 - 85
  • [37] A probabilistic model to assess the cost-effectiveness of a new statin (Rosuvastatin) in the UK
    Palmer, S
    Brady, AJ
    Ratcliffe, A
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 649 - 650
  • [38] The cost-effectiveness of adherence therapy for people with schizophrenia
    Patel, A
    McCrone, P
    Knapp, M
    Martijn, K
    Helm, H
    Amaddeo, F
    Leese, M
    Moreno, M
    [J]. EUROPEAN PSYCHIATRY, 2005, 20 : S249 - S249
  • [39] Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal
    Marques, Andrea
    Lourenco, Oscar
    Ortsater, Gustaf
    Borgstrom, Fredrik
    Kanis, John A.
    da Silva, Jose Antnio P.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2016, 99 (02) : 131 - 141
  • [40] Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal
    Andréa Marques
    Óscar Lourenço
    Gustaf Ortsäter
    Fredrik Borgström
    John A. Kanis
    José António P. da Silva
    [J]. Calcified Tissue International, 2016, 99 : 131 - 141
12345